A Phase II/III, Open Label, Multicenter Study to Evaluate the Safety, Reactogenicity and Immunogenicity of the Whole-Virion Inactivated SARS-CoV-2 Vaccine (COVAXIN®) in Healthy Volunteers Ages ≤18 to ≥ 2 Years.
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Enrollment
- 525
- Locations
- 14
- Primary Endpoint
- Reactogenicity
Study Overview
Brief Summary
The study is designed to evaluate the safety, reactogenicity and immunogenicity of three groups ages ≤18 - >12, ≤12 ->6, ≤ 6 - >2 years of healthy volunteers who receive two doses of the whole virion inactivated SARS-CoV-2 virus vaccine (COVAXIN®) 28 days apart.
Data will be un-blinded to the third party bio-statistician and an interim analysis will be performed on day 56 for Immunogenicity, Safety and submitted to CDSCO.
Detailed Description
Study design: A Phase II/III, Open Label, Multicenter Study to Evaluate the Safety, Reactogenicity and Immunogenicity, of the Whole-Virion Inactivated SARS-CoV-2 Vaccine (COVAXIN®) in Healthy Volunteers ages ≤18 to ≥2 Years.
A total sample size of 525 healthy volunteers.
The study is designed to evaluate the safety, reactogenicity and immunogenicity of three groups ages ≤18 - >12, ≤12 ->6, ≤ 6 - >2 years of healthy volunteers who receive two doses of the whole virion inactivated SARS-CoV-2 virus vaccine (COVAXIN®) 28 days apart.
Group1: A total of 175 healthy volunteers ages ≤18->12, years will be enrolled in this group and will receive two doses of BBV152 vaccine through intramuscular route on Day 0 and Day 28+2.
Group 2: A total of 175 healthy volunteers ages ≤12->6, years will be enrolled in this group and will receive two doses of BBV152 vaccine through intramuscular route on Day 0 and Day 28+2.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Prevention
- Masking
- None
Eligibility Criteria
- Ages
- 2 Years to 18 Years (Child, Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Ability to provide written informed consent (by the parents or legally acceptable/authorized representative (LAR) and assent by the children (verbal/oral assent for the children of age between 7-12 years, and written assent for the children of age between >12 to 18 years), and Audio video consent for all participants.
- •Participants of either gender of age between ≥2 to ≤18years (Participant should be ≤18 years at the time of Screening of the study).
- •Good general health as determined by the discretion of investigator.
- •Expressed interest and availability to fulfill the study requirements.
- •Agrees not to participate in another clinical trial at any time during the study period.
- •Agrees to remain in the study area for the entire duration of the study.
- •Willing to allow storage and future use of biological samples for future research.
Exclusion Criteria
- •History of any other COVID-19 investigational vaccination.
- •Confirmed SARS-CoV-2 at the time of screening using RT-PCR and ELISA method.
- •Temperature >38.0°C (100.4°F) or symptoms of an acute self-limited illness such as an upper respiratory infection or gastroenteritis within three days prior to each dose of vaccine.
- •Receipt of an experimental agent (vaccine, drug, device, etc.) within 60 days before enrollment or expects to receive an investigational agent during the study period.
- •Receipt of any licensed vaccine within four weeks before enrollment in this study.
- •Known sensitivity to any ingredient of the study vaccines, or a more severe allergic reaction and history of allergies in the past.
- •Receipt of immunoglobulin or other blood products within the three months prior to vaccination in this study.
- •Immunosuppression as a result of an underlying illness or treatment with immunosuppressive or cytotoxic drugs, or use of anticancer chemotherapy or radiation therapy within the preceding 36 months.
- •Long-term use (>2 weeks) of oral or parenteral steroids (glucocorticoids) or high-dose inhaled steroids (>800 mcg/day of beclomethasone dipropionate or equivalent) within the preceding six months (nasal and topical steroids are allowed).
- •Any history of hereditary angioedema or idiopathic angioedema.
- •Any history of anaphylaxis in relation to vaccination.
- •History of congenital diseases.
- •Any history of albumin-intolerance.
- •History of any cancer.
- •History of psychiatric severe conditions likely to affect participation in the study.
- •A bleeding disorder (e.g. factor deficiency, coagulopathy or platelet disorder, or prior history of significant bleeding or bruising following IM injections or venepuncture.
- •Any other serious chronic illness requiring hospital specialist supervision.
- •Respiratory diseases like severe acute respiratory syndrome (SARS), including mild asthma.
- •Chronic cardiovascular disease, gastrointestinal disease, liver disease, renal disease, endocrine disorder, and neurological illness
- •History of SARS-CoV-2 infection or known close contact with anyone with laboratory-confirmed SARS-CoV-2 infection or COVID-19 within 2 weeks prior to vaccine administration.
- •Any other condition that in the opinion of the investigator would jeopardize the safety or rights of a volunteer participating in the trial or would render the subject unable to comply with the protocol.
- •Re-Vaccination Exclusion Criteria
- •Anaphylactic reaction following administration of the investigational vaccine.
- •Virologically confirmed cases of COVID-19
Outcomes
Primary Outcomes
Reactogenicity
Time Frame: Within 7 days after each dose of vaccination
Occurrence of Solicited Adverse events
Immunogenecity
Time Frame: 6 months
GMTs of SARS-CoV-2 virus neutralizing antibodies by MNT/PRNT assay.
Secondary Outcomes
- Immunogenicity(6 months)